AbbVie and Principia ally on development of immunology therapies

AbbVie has announced a new collaboration with Principia Biopharma that aims to create new oral immunoproteasome inhibitor therapies.

The aim of this partnership will be to produce first-in-class oral therapies that can deliver the benefits of proteasome inhibition safely within the field of immunology, with AbbVie and Principia to collaborate on research and preclinical studies.

Both companies will contribute their expertise to assist the development of orally bioavailable, selective inhibitors of the immunoproteasome subunits to target autoimmunity, utilising Principia's Tailored Covalency platform of reversible covalent inhibitors.

Upon successful completion of these studies, AbbVie will assume responsibility for the ongoing clinical development and commercialisation of any viable compounds resulting from the partnership.

Lisa Olson, vice-president for immunology research at AbbVie, said: "The combination of AbbVie's world-class expertise in immunology drug development with Principia's innovative approach to immunoproteasome inhibitors may offer patients a new class of therapies to treat serious and chronic conditions."

AbbVie was recently named as the most reputable pharmaceutical company of 2017 in the Reputation Institute's Global Pharma RepTrak study, underlining the progress it has made since its foundation five years ago.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.